Health Care Professionals (HCPs) Attendees: Please complete the following Post-activity survey and evaluation questions so we can review our events goals, objectives, and topics.

Question Title

* 1. Please provide the following information:

Question Title

* 2. Rate your experience for congress program's scientific quality, congress virtual platform, and participating in this learning event:

Question Title

* 3. Would you consider attending EUSTM-2024 Congress next year ?

Question Title

* 4. Urothelial Carcinoma Symposium: On a scale of 0 (worst possible rating) to 10 (best possible rating), please rate your overall satisfaction:

0 10

Question Title

* 5. Urothelial Carcinoma Symposium: Please rate your current level of knowledge in the learning objectives, following the event:

Question Title

* 6. Urothelial Carcinoma Symposium: I feel this symposium addressed the learning objectives:

Question Title

* 7. Urothelial Carcinoma Symposium: The content was presented in a balanced manner:

Question Title

* 8. Urothelial Carcinoma Symposium: The speakers were knowledgeable and interesting on the topic:

Question Title

* 9. Sacitizumab Govitecan is an Antibody Drug Conjugate that targets...

Question Title

* 10. A 72 years-old male with metastatic urothelial carcinoma, treated with 4 cycles of cisplatin and gemcitabine, CT scan suggested a very good response. How would you manage this patient?

Question Title

* 11. A 65 years-old female with poorly controlled diabetes, now with muscle-invasive bladder carcinoma with metastasis to the liver, disease progressed after chemo with carboplatin, gemcitabine and pembrolizumab. NGS no target mutation. How would you treat next?

Question Title

* 12. A 66-year-old male patient is diagnosed with mUC, he has an ECOG 1, labs are unremarkable except for a GFR of 52, and he has no grade 3 sequelae from his treatment. He has previously received carboplatin with gemcitabine during neoadjuvant therapy, pembrolizumab, and enfortumab vedotin for advanced disease—which of the following statements is true?

Question Title

* 13. A 72-year-old male patient with refractory mUC is enrolled in a clinical study of the Her2-directed antibody trastuzumab deruxtecan. Initial treatment is uneventful, but three months into treatment, the patient presents to the ER with worsening exertional dyspnea and cough. Which of the following is likely to be the drug-associated adverse event to explain his presentation?

Question Title

* 14. Which of the following statements is true?

Question Title

* 15. A 65 year-old woman received gemcitabine and cisplatin for metastatic UC, had a partial response after 6 cycles, developed grade 1 peripheral neuropathy, received avelumab, had PD after 3 cycles, was started on enfortumab vedotin (EV) 1.25 mg/kg day 1, 8, 15 q28days, developed grade 2 peripheral neuropathy after 3 cycles.

What will you do next?

Question Title

* 16. A 70 years-old man on EV 1.25 mg/kg develops a generalized maculopapular rash over trunk, back and extremities, with itching

What will you do?

Question Title

* 17. A 73 years-old man on EV 1.25 mg/kg, BMI 35 has blood glucose level of 320 mg/dL on the day of EV treatment

What will you do?